-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – MK-4830 in Metastatic Breast Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - MK-4830 in Metastatic Breast Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. MK-4830 in Metastatic Breast Cancer Drug Details: MK-4830 is under development...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Tazemetostat Hydrobromide in Rhabdomyosarcoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Tazemetostat Hydrobromide in Rhabdomyosarcoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Tazemetostat Hydrobromide in Rhabdomyosarcoma Drug Details: Tazemetostat hydrobromide (Tazverik) is an anti-neoplastic...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – C1 Esterase Inhibitor (Human) in Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - C1 Esterase Inhibitor (Human) in Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. C1 Esterase Inhibitor...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – LB-1908 in Esophageal Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - LB-1908 in Esophageal Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. LB-1908 in Esophageal Cancer Drug Details: LB-1908 (LCAR-C18S) is under development for...
-
Product Insights
Hemophilia A (Factor VIII Deficiency) Clinical Trial Analysis by Phase, Trial Status, End Point, Sponsor Type and Region, 2024 Update
A total of 721 Hemophilia A (Factor VIII Deficiency) clinical trials were conducted as of February 2024. The Hemophilia A clinical trial report provides a comprehensive understanding of the Hemophilia A (Factor VIII Deficiency) clinical trial scenario across regions, and countries (G7 & E7), along with insights into the various phases, trial status, and end points status. The report also includes information about the sponsor type and the prominent sponsors associated with the trials. Key Regions ·       Asia-Pacific ·       Europe...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Danburstotug in T-Cell Lymphomas
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Danburstotug in T-Cell Lymphomas Drug Details: STIA-1015 is under development for the treatment of solid...
-
Product Insights
Fibrinogen Deficiency (Factor I Deficiency) – Drugs In Development, 2023
Global Markets Direct’s, ‘Fibrinogen Deficiency (Factor I Deficiency) - Drugs In Development, 2023’, provides an overview of the Fibrinogen Deficiency (Factor I Deficiency) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Fibrinogen Deficiency (Factor I Deficiency), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Immune Globulin (Human) in Neuropathy
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Immune Globulin (Human) in Neuropathy report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Immune Globulin (Human) in Neuropathy Drug Details: Human normal immunoglobulin (Octagam, ...
-
Product Insights
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) – Drugs In Development, 2023
Global Markets Direct’s, ‘Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) - Drugs In Development, 2023’, provides an overview of the Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest...
-
Product Insights
Peripheral Neuropathy (Sensory Neuropathy) – Drugs In Development, 2023
Global Markets Direct’s, ‘Peripheral Neuropathy (Sensory Neuropathy) - Drugs In Development, 2023’, provides an overview of the Peripheral Neuropathy (Sensory Neuropathy) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Peripheral Neuropathy (Sensory Neuropathy), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press...